Skip to main content
Top
Published in: Annals of Surgical Oncology 5/2019

01-05-2019 | Liver Transplantation | ASO Author Reflections

ASO Author Reflections: Liver Transplantation for Hepatocellular Carcinoma

Authors: Tiffany C. L. Wong, MBBS, Kelvin K. C. Ng, MD

Published in: Annals of Surgical Oncology | Issue 5/2019

Login to get access

Excerpt

It is controversial if living donor liver transplantation (LDLT) and deceased donor liver transplantation (DDLT) offer similar outcomes for hepatocellular carcinoma (HCC). Studies that compared the outcomes of LDLT and DDLT for HCC drew contradictory conclusions. LDLT and DDLT are different in terms of graft availability, allocation, waiting time, need for bridging therapy, risk of dropout, surgical technique, and graft size. The potential concerns of LDLT for HCC include a fast tracking effect and the possibility of higher tumor recurrence after transplant.1 The caveat is that survival data were evaluated from the time of transplant rather than from the time of listing, therefore the effect of waiting time and dropout was not considered. Another key issue is that LDLT patients tend to have more advanced tumor stage and have more salvage transplant. There were two reports from the French centers that evaluated outcomes of HCC patients from the time of listing but did not demonstrate any survival difference.2,3
Literature
1.
go back to reference Lo C, Fan S, Liu C, Chan S, Ng I, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg. 2007;94(1):78–86.CrossRefPubMed Lo C, Fan S, Liu C, Chan S, Ng I, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg. 2007;94(1):78–86.CrossRefPubMed
2.
go back to reference Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology. 2011;53(5):1570–1579.CrossRefPubMed Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology. 2011;53(5):1570–1579.CrossRefPubMed
3.
go back to reference Azoulay D, Audureau E, Bhangui P, Belghiti J, Boillot O, Andreani P, et al. Living or brain-dead donor liver transplantation for hepatocellular carcinoma: a multicenter, western, intent-to-treat cohort study. Ann Surg. 2017;266(6):1035–1044.CrossRefPubMed Azoulay D, Audureau E, Bhangui P, Belghiti J, Boillot O, Andreani P, et al. Living or brain-dead donor liver transplantation for hepatocellular carcinoma: a multicenter, western, intent-to-treat cohort study. Ann Surg. 2017;266(6):1035–1044.CrossRefPubMed
5.
go back to reference Li CX, Ling CC, Shao Y, Xu A, Li XC, Ng KT, et al. CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. J Hepatol. 2016;65(5):944–952.CrossRefPubMed Li CX, Ling CC, Shao Y, Xu A, Li XC, Ng KT, et al. CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. J Hepatol. 2016;65(5):944–952.CrossRefPubMed
Metadata
Title
ASO Author Reflections: Liver Transplantation for Hepatocellular Carcinoma
Authors
Tiffany C. L. Wong, MBBS
Kelvin K. C. Ng, MD
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07199-w

Other articles of this Issue 5/2019

Annals of Surgical Oncology 5/2019 Go to the issue